(Bloomberg) — Pfizer Inc. won't bring an over-the-counter version of its cholesterol pill Lipitor to the U.S. market, after a trial found that patients couldn't take the drug correctly without a doctor's help.

Pfizer's decision to kill the over-the-counter program ends a years-long effort designed to preserve sales of what was once the New York-based company's — and the world's — top-selling drug. Since losing patent protection in 2011, Lipitor's sales have fallen from more than $10 billion a year to $2.06 billion last year.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.